Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Siplizumab in T1DM
NCT05574335 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE1/PHASE2 · terminated · last registry update 2026-07-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Prior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lymphodepletion. The pharmaceutical partner decided not to reopen its own T1D trial and ceased development of siplizumab in autoimmunity.” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: ITB-Med LLC, TCD601 (NCT04803006)
- 2026-11-04Also stopped (terminated): ITB-Med LLC, TCD601 (NCT04803006)
- 2026-07-17Also stopped (terminated): ITB-Med LLC, TCD601 (NCT06453668)
- 2026-07-13Also stopped (terminated): ITB-Med LLC, TCD601 (NCT04803058)
- 2026-06-10Also stopped (terminated): Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2026-03-12Results posted on the registry: ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-03-12Also stopped (terminated): ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-02-27Results posted on the registry: Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2025-08-14Also stopped (terminated): ITB-Med LLC, TCD601 (NCT06025110)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision